Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
6.28
+0.21 (3.38%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Trevi Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Trevi Therapeutics stock have an average target of 17.56, with a low estimate of 7.00 and a high estimate of 29. The average target predicts an increase of 179.84% from the current stock price of 6.28.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Trevi Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 6 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +282.47% | Apr 8, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Reiterates $11 → $20 | Strong Buy | Reiterates | $11 → $20 | +218.73% | Mar 19, 2025 |
| Needham | Needham | Strong Buy Maintains $25 → $24 | Strong Buy | Maintains | $25 → $24 | +282.47% | Mar 19, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +234.66% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +99.20% | Mar 19, 2025 |
Financial Forecast
Revenue This Year
n/a
from 171.27M
Revenue Next Year
n/a
EPS This Year
-0.53
from -0.47
EPS Next Year
-0.60
from -0.53
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.43 | -0.28 | -0.20 | ||
| Avg | -0.53 | -0.60 | -0.73 | ||
| Low | -0.68 | -0.81 | -1.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.